By Sriparna Roy (Reuters) -Eli Lilly agreed to buy Morphic Holding (NASDAQ:MORF) for $3.2 billion in cash, the companies said on ...
Regulatory approvals for Kisunla, Ebglyss, and Zepbound in 2024 were noted as critical milestones, alongside the acquisition of Morphic Therapeutics ... differentiation. Eli Lilly ended 2024 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback